As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

Ryan Fischesser Biography and Net Worth

VP of Caribou Biosciences

Ryan is the Vice President of Finance and Controller for Caribou Biosciences. Ryan began his career in public accounting over a decade ago with a focus on audit and accounting services. In 2012, he co-founded the CPA firm BHLF LLP where he provided audit and outsourced accounting services to clients in the life science, waste management, and airline industries. He received his B.S. degree in Business Administration with an emphasis in financial services from Saint Mary’s College of California and is a licensed Certified Public Accountant in California.

What is Ryan Fischesser's net worth?: The estimated net worth of Ryan Fischesser is at least $222,939.32 as of October 6th, 2022. Mr. Fischesser owns 110,366 shares of Caribou Biosciences stock worth more than $222,939 as of November 24th. This net worth approximation does not reflect any other assets that Mr. Fischesser may own. Learn More about Ryan Fischesser's net worth.
How do I contact Ryan Fischesser?: The corporate mailing address for Mr. Fischesser and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Ryan Fischesser's contact information.
Has Ryan Fischesser been buying or selling shares of Caribou Biosciences?: Ryan Fischesser has not been actively trading shares of Caribou Biosciences during the past quarter. Most recently, Ryan Fischesser sold 10,000 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $10.80, for a transaction totalling $108,000.00. Following the completion of the sale, the vice president now directly owns 110,366 shares of the company's stock, valued at $1,191,952.80. Learn More on Ryan Fischesser's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Ryan Fischesser Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	10,000	$10.80	$108,000.00	110,366
1/11/2022	Buy	7,387	$4.00	$29,548.00
12/20/2021	Buy	1,136	$2.69	$3,055.84
10/11/2021	Buy	1,746	$2.69	$4,696.74

Ryan Fischesser Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $2.02

$1.93

$2.05

50 Day Range

MA: $2.04

$1.77

$2.79

2 Week Range

Now: $2.02

$1.50

$8.33

Volume

989,411 shs

Average Volume

1,914,823 shs

Market Capitalization

$182.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.